{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:01:54Z","timestamp":1762866114331,"version":"3.40.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ejphar.2013.03.029","type":"journal-article","created":{"date-parts":[[2013,3,22]],"date-time":"2013-03-22T15:47:39Z","timestamp":1363967259000},"page":"30-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Identification of novel pyrazoloquinazolinecarboxilate analogues to inhibit nerve growth factor in vitro"],"prefix":"10.1016","volume":"708","author":[{"given":"Joseph K.","family":"Eibl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget C.","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2013.03.029_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuron.2006.12.018","article-title":"High affinity not in the vicinity?","volume":"53","author":"Barker","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2013.03.029_bib2","first-page":"94","article-title":"Tanezumab, a recombinant humanised mAb against nerve growth factor for the treatment of acute and chronic pain","volume":"12","author":"Cattaneo","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ejphar.2013.03.029_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/CS20050163","article-title":"Neurotrophin signalling in health and disease","volume":"110","author":"Chao","year":"2006","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ejphar.2013.03.029_bib4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1124\/jpet.104.066225","article-title":"Differential activity of the nerve growth factor (NGF) antagonist PD90780 [7-(benzolylamino)-4,9-dihydro-4-methyl-9-oxo-pyrazolo[5,1-b]quinazoline-2 -carboxylic acid] suggests altered NGF-p75NTR interactions in the presence of TrkA","volume":"310","author":"Colquhoun","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2013.03.029_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1126\/science.1152677","article-title":"A model for neuronal competition during development","volume":"320","author":"Deppmann","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2013.03.029_bib6","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.109.159079","article-title":"Multipotent neurotrophin antagonist targets brain-derived neurotrophic factor and nerve growth factor","volume":"332","author":"Eibl","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2013.03.029_bib7","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.neuint.2012.10.008","article-title":"Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor","volume":"61","author":"Eibl","year":"2012","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2013.03.029_bib8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/hmg\/ddh096","article-title":"A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception","volume":"13","author":"Einarsdottir","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejphar.2013.03.029_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nbt0311-173","article-title":"Fate of novel painkiller mAbs hangs in balance","volume":"29","author":"Garber","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejphar.2013.03.029_bib10","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1126\/science.1095190","article-title":"Structure of nerve growth factor complexed with the shared neurotrophin receptor p75","volume":"304","author":"He","year":"2004","journal-title":"Science"},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2013.03.029_bib11","doi-asserted-by":"crossref","first-page":"I20","DOI":"10.1007\/s102860200016","volume":"12","author":"Indo","year":"2002","journal-title":"Clin. Auton. Res."},{"key":"10.1016\/j.ejphar.2013.03.029_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF00124474","article-title":"Scoring noncovalent protein\u2013ligand interactions: a continuous differentiable function tuned to compute binding affinities","volume":"10","author":"Jain","year":"1996","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejphar.2013.03.029_bib13","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa0901510","article-title":"Tanezumab for the treatment of pain from osteoarthritis of the knee","volume":"363","author":"Lane","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2013.03.029_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejphar.2013.03.029_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/ALN.0b013e31821b1ac5","article-title":"Antagonism of nerve growth factor-TrkA signaling and the relief of pain","volume":"115","author":"Mantyh","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejphar.2013.03.029_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/354411a0","article-title":"New protein fold revealed by a 2.3-A resolution crystal structure of nerve growth factor","volume":"354","author":"McDonald","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2013.03.029_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/1097-4547(20000801)61:3<263::AID-JNR4>3.0.CO;2-M","article-title":"NGF ligand alters NGF signaling via p75(NTR) and trkA","volume":"61","author":"Niederhauser","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2013.03.029_bib18","doi-asserted-by":"crossref","unstructured":"Ochodnicky, P., Cruz, C.D., Yoshimura, N., Michel, M.C., 2011. Nerve growth factor in bladder dysfunction: contributing factor, biomarker, and therapeutic target. Neurourol. Urodyn.","DOI":"10.1002\/nau.21022"},{"key":"10.1016\/j.ejphar.2013.03.029_bib19","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0022-3565(24)38269-2","article-title":"Characterisation of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat","volume":"289","author":"Owolabi","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2013.03.029_bib20","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.1021\/jm030221q","article-title":"Molecular basis of neurotrophin\u2013receptor interactions","volume":"46","author":"Pattarawarapan","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2013.03.029_bib21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/07853890802698842","article-title":"Challenges in monoclonal antibody-based therapies","volume":"41","author":"Samaranayake","year":"2009","journal-title":"Ann. Med."},{"key":"10.1016\/j.ejphar.2013.03.029_bib22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1006\/bbrc.1995.2802","article-title":"PD 90780, a non-peptide inhibitor of nerve growth factor\u2019s binding to the P75 NGF receptor","volume":"217","author":"Spiegel","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2013.03.029_bib23","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1126\/science.1071552","article-title":"Signaling pathways for PC12 cell differentiation: making the right connections","volume":"296","author":"Vaudry","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2013.03.029_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/0063030-200822060-00002","article-title":"Targeting nerve growth factor in pain: what is the therapeutic potential?","volume":"22","author":"Watson","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejphar.2013.03.029_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.neuron.2006.09.034","article-title":"Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors","volume":"53","author":"Wehrman","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2013.03.029_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neuron.2010.09.007","article-title":"Molecular mechanisms of synaptic specificity in developing neural circuits","volume":"68","author":"Williams","year":"2010","journal-title":"Neuron"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299913002197?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299913002197?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T01:35:59Z","timestamp":1745976959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299913002197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":26,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0014299913002197"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2013.03.029","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of novel pyrazoloquinazolinecarboxilate analogues to inhibit nerve growth factor in vitro","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2013.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}